FDA releases draft guidance on reducing testing on non-human primates for monoclonal antibodies

FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.”

Disappointment hangs in the air as Replimune’s Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab in the treatment of advanced melanoma was denied again by FDA on April 10.

UT San Antonio awarded $44M NIH contract to advance landmark RURAL Cohort Study

The University of Texas at San Antonio has been awarded a five-year, $44 million contract from the National Heart, Lung, and Blood Institute for a study focused on persistent health challenges in the rural South.

May 01, 2026

Vol.52 No.17

Drugs & Targets

ODAC recommends against approval of camizestrant NDA, gives a nod to sNDA for capivasertib

The FDA Oncologic Drugs Advisory Committee on April 30 considered two applications from AstraZeneca Pharmaceuticals LP.

FDA accepts NDA for zipalertinib for NSCLC with mutations

FDA has accepted a New Drug Application for zipalertinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy, with or without amivantamab. The Prescription Drug User Fee Act target action date is Feb. 27, 2027.

May 01, 2026

Vol.52 No.17

Drugs & Targets

FDA grants priority review for Ziihera in first-line HER2+ GEA

FDA has accepted for filing with Priority Review the supplemental Biologics License Application for Ziihera (zanidatamab-hrii) containing combinations for the first-line treatment of adult patients with HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal junction, or gastroesophageal adenocarcinoma.

May 01, 2026

Vol.52 No.17

NCI

At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.”

Tucked in at the end of a 20-minute talk that covered paylines, promising young investigators, and precision medicine, NCI Director Anthony G. Letai beefed up the alliteration with two more words that begin with a “p”: prevention and pilot.

April 24, 2026

Vol.52 No.16

By Sara Willa Ernst

FDA releases draft guidance on reducing testing on non-human primates for monoclonal antibodies

YOU MAY BE INTERESTED IN

FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.”

UT San Antonio awarded $44M NIH contract to advance landmark RURAL Cohort Study

ODAC recommends against approval of camizestrant NDA, gives a nod to sNDA for capivasertib

FDA accepts NDA for zipalertinib for NSCLC with mutations

FDA grants priority review for Ziihera in first-line HER2+ GEA

At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.”

Renew today!

Subscriber content

Never miss an issue!

Login

FDA releases draft guidance on reducing testing on non-human primates for monoclonal antibodies

YOU MAY BE INTERESTED IN

FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients“Patients are owed another review.”

UT San Antonio awarded $44M NIH contract to advance landmark RURAL Cohort Study

ODAC recommends against approval of camizestrant NDA, gives a nod to sNDA for capivasertib

FDA accepts NDA for zipalertinib for NSCLC with mutations

FDA grants priority review for Ziihera in first-line HER2+ GEA

At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylinesThere’s “clear evidence that funding is moving and the system is working.”

Never miss an issue!

Login

FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.”

At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.”